Roche Wins Expanded European Approval for Pegasys
The European Medicines Agency, or EMA, has awarded Big Pharma Roche expanded approval for its antiviral Pegasys, alongside ribavirin, in treating chronic hepatitis C virus, or HCV. The EMA's expanded approval will now allow Roche to treat HCV-positive children aged 5 and older with the drug who have not yet begun treatment, according to a statement from the company.
Roche first won European approval for Pegasys in treating adults with chronic HCV more than a decade ago; regulators in China and the U.S. have approved it as well. Around 65,000 European children suffer from chronic HCV; while Roche states that many sufferers of the disease show few if any symptoms, it is progressive and can afflict patients with life-threatening ailments such as liver damage.
Dr. Hal Barron, Roche's chief medical officer and global product development Head talked about the new indication's benefit for children with the disease, saying in the release: "Hepatitis C can ultimately lead to the development of advanced liver disease if left untreated. This approval provides doctors and parents of children as young as five with a treatment combination for this infection."
The article Roche Wins Expanded European Approval for Pegasys originally appeared on Fool.com.Fool contributor Dan Carroll and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.